Dr. David R. Spigel, MD
Claim this profileTennessee Oncology
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
29 reported clinical trials
54 drugs studied
About David R. Spigel, MD
Education:
- MD from the University of Texas Southwestern Medical School, 1991.
- Completed Residency in Internal Medicine at Vanderbilt University Medical Center, 1994.
- Fellowship in Hematology/Oncology at Vanderbilt University Medical Center, 1996.
Experience:
- Since 1996, serves as Chief Scientific Officer and Director of the Lung Cancer Research Program at Tennessee Oncology.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
metastatic
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials David R. Spigel, MD is currently running
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting1 award Phase 211 criteria
Chiauranib
for Advanced Cancers
This trial is testing a new drug called chiauranib for patients with advanced cancers that don't respond to standard treatments. It aims to block the signals that cancer cells need to grow. The focus is on patients with small cell lung cancer that has worsened after previous treatments.
Recruiting1 award Phase 1 & 28 criteria
More about David R. Spigel, MD
Clinical Trial Related4 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments David R. Spigel, MD has experience with
- Pembrolizumab
- Gemcitabine
- Rituximab
- Niraparib
- PD-1 Inhibitor
- LYL797
Breakdown of trials David R. Spigel, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David R. Spigel, MD specialize in?
David R. Spigel, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is David R. Spigel, MD currently recruiting for clinical trials?
Yes, David R. Spigel, MD is currently recruiting for 6 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that David R. Spigel, MD has studied deeply?
Yes, David R. Spigel, MD has studied treatments such as Pembrolizumab, Gemcitabine, Rituximab.
What is the best way to schedule an appointment with David R. Spigel, MD?
Apply for one of the trials that David R. Spigel, MD is conducting.
What is the office address of David R. Spigel, MD?
The office of David R. Spigel, MD is located at: Tennessee Oncology, Nashville, Tennessee 37203 United States. This is the address for their practice at the Tennessee Oncology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.